

# Observatory on the impact of the COVID-19 pandemic on the access to treatments

2020-2021

Study performed by IQVIA with the non conditioning support of Farmindustria

© 2021. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.

#### Premise and objectives of the study

The pandemic had important effects on the initiation of treatments and access to treatments, with significant consequences on the clinical outcomes

The sanitary emergency that hit the country is having a significative impact on the healthcare system. The complexity of the pandemic and the issues related to the management of infected people challenged the healthcare system with the saturation of hospitals and intensive care, the need of defining procedures and paths dedicated to Covid-19 patients and the home management of patients. Moreover, the pandemic produced a minor access to treatments for other diseases like oncological, cardiological and respiratory ones. In fact, along with the concerns related to the management of infected patients, the extended lockdown had important effects also on the access to visits and treatments of non-Covid patients producing significant consequences for patients' health and healthcare system organization (hospital-territory integration, remote patient management).

In this context IQVIA with the non conditioning contribution of Farmindustria realized a study, to be updated every three months, through an ad-hoc observatory to monitor the impact of the pandemic on the access to diagnosis and treatments and its evolution in the following months. The study is based on the analysis of Real World Data gathered from a sample of 900 general practitioners and a panel of 450 onco-hematologists representative of the reference universes.

In this document the data related to the january-october 2020 period in comparison with the same period in 2019 are presented. The study will follow for the entire 2021 with quarterly updates.



#### **Main findings**

The contraction of the entire pharmaceutical sector (-3% MAT 09/2020) - for the first time in recent years – unveils the limitations of access to treatments both in the hospital and in the pharmacy.

In the first ten months of 2020 it has been detected a significant decrease in the access to diagnosis and treatments in the main therapeutic areas compared to the same period of the previous year.

#### **DATA SOURCE**

IQVIA LPD (Longitudinal Patient Database) Records collected from the patient management software – Panel of 900 GPs

**Oncology Dynamics**: collection of patients data forms - Panel of 450 oncohematologists

- In the main respiratory and cardio-metabolic pathologies it has been identified a significant contraction of the new diagnosis (-521.000 equal to a reduction of 12%), new treatments initiations (-277.000, -10%), specialistic visits (-1,5 million, 30%) and requests of exams (-2.415.000, 22%).
- In the **respiratory** area (COPD/asthma) it is observed a significant drop in new diagnosis (COPD: -62.000; Asthma: -158.000), new treatments (-46.000, -124.000), referral to specialists (-123.000, -129.000) and spirometry requests (-108.000, -127.000). The underlined drop during the first lockdown is present also in the following period. In the **cardiovascular area** (atrial fibrillation/hearth failure) it is detected a significant contraction in new diagnosis (atrial fibrillation -18.000, hearth failure -44.000), new treatments (-4.000, -29.000), referrals to cardiologist (-81.000, -248.000) and requests of ECG (-64.000, -180.000). The slight improvement after the lockdown did not balance the losses.
- Also, in the oncological area there is a significant contraction of access to diagnosis and treatments. In the first lockdown period 18.000 postponed diagnosis are estimated. The partial recovery in the summer months did not balance the drop: overall in october there are 30.000 cancer diagnosis less than the ones made in the same period of the previous year. In particular, in the first 10 months there is a reduction of the screening requests for breast (-7%), lung (-10%) and colon (-10%) cancer. In addition, it is noted a contraction of new diagnosis for cancer (-11%), treatments initiations (-14%), surgeries (-17%) and hospitalization (-14%). After the initial interruption of screening and follow up visits, due to the closure of many departments and ambulatories, it has been observed a partial recovery during summer months, but it did not offset the contraction of diagnosis and treatments. Subsequently in parallel to the second pandemic wave it has been detected a new reduction in the accesses.



## The contraction of the pharmaceutical sector (-3%) shows the limitation of access to treatments both in hospital and pharmacy

Evolution of the pharmaceutical during MAT 9/2020



Values are expressed considering the weighted average price for the hospital channel and direct purchases (included the DPC channel), ex-factory for pharmacy channel - Class A, A with note, Class C and Class H are taken into account Source: IQVIA National Integrated Database September 2020 © IQVIA 2020. All rights reserved.



The first Covid-19 wave significantly affected the number of new diagnosis and treatments, in addition to the requests of specialistic visits and exams


Dato Real World Data from GP – FOCUS: COPD, ASTHMA, ATRIAL FIBRILLATION, HEARTH FAILURE, HYPERTENSION, DIABETES

-521.000	-277.000	-1.498.000	-2.415.000
[-12%]	[-10%]	[-30%]	[-22%]
NEW DIAGNOSIS	NEW TREATMENTS	REFERRALS TO SPECIALISTS	TESTS/EXAMS

△ january-october 2020 vs 2019 YoY



## In the first 10 months of the year, there was an important contraction of new diagnosis, treatments and referrals to specialists among chronic pathologies





Data source: IQVIA Longitudinal Patient Database (january 2019- october 2020)  $\circledcirc$  IQVIA 2020. All rights reserved.


RIMARY CARE AREA

In the COPD area it is detected a significant drop of new diagnosis (-20%), new treatments (-19%), referral to specialists (-35%) and spirometry requests (-42%). The drop underlined after the first lockdown worsened during the year

#### COPD: comparison january-october 2020 vs 2019









Data source: IQVIA Longitudinal Patient Database (january 2019- october 2020) © IQVIA 2020. All rights reserved. FIT COPD

Also, in the asthma area it is observed a significative contraction of new diagnosis (-17%), new treatments (-16%), referrals to specialist (-40%) and spirometry requests (-41%). The drop underlined after the first lockdown became even worse during the year


#### Asthma: comparison january-october 2020 vs 2019





 Between february and june 2020 the referrals to pulmonologist for asthma decreased by 54% with respect to the same period in 2019
 Since the beginning

of the year, specialistic visit requests for asthma reduced by ~129.000



Between february and june 2020 spirometry requests for asthma dropped by 55% with respect to the same period in 2019
Since the beginning of the year, there has been a drop of


~127.000 spirometries for asthma

= IC

/I A

In atrial fibrillation area there has been a significative contraction of new diagnosis (-13%), new treatments (-11%), referrals to specialist (-31%) and ECG requests (-28%) starting from the beginning of the year. The slight recovery after the lockdown did not balance the losses


Atrial fibrillation: comparison january-october 2020 vs 2019




© IQVIA 2020. All rights reserved.

#### Also, the health failure witnessed a drop during the lockdown, followed by a partial recovery that does not offset the losses: there is a reduction of new diagnosis (-10%), new treatments (-4%), referrals to specialist(-30%) and ECG requests (-27%)

Health failure: comparison january-october 2020 vs 2019










 Between february and june 2020 ECG requests for hearth failure decreased by 37% with respect to the same period in 2019


🕅 HEALTH FAILURE


 Since the beginning of the year, there has been a drop of ~64.000 ECG for hearth failure

## Hypertension had a significant fall during the lockdown, followed by a subsequent partial recovery: in october it is observed a contraction in new diagnosis (-9%), new treatments (-4%), referrals to specialist (-32%) and ECG requests (-30%)

#### Hypertension: comparison january-october 2020 vs 2019








र्दे **DIABETES** Diabetes had an important drop during the lockdown, which has not been recovered yet : since the beginning of 2020 there is a contraction in new diagnosis (-8%), new treatments (-5%), referrals to specialist (-20%) and glycemia tests (-15%)


#### Diabetes: comparison january-october 2020 vs 2019



#### (°¢) ONCOOGICAL SCREENING

#### From early 2020 in the oncological area the screening requests for breast, lung and colon decreased by 7-10%, despite the partial recovery in summer months of the screening

#### Oncological screening: comparison january-october 2020 vs 2019



- april 2020, (-64%)
- Between iune and september it is observed an increase of 27% vs 2019, that is guite substantial in june (+52%)
- In october there is another drop of 14% vs 2019


- april 2020, (-43%)
- · Between june and september it is observed an increase of 9% vs 2019, that is guite substantial in june (+53%)
- In october there is another drop of 25% vs 2019

- april 2020, (-65%)
- Starting from june, there is an increase of 26% vs 2019; the increase is more substantial in june (+51%), that was followed by ups and down



New diagnosis for cancer, treatment initiations, surgeries and hospitalizations dropped by 11-17% with respect to the previous year. The partial recovery in summer months did not offset the losses. They are estimated around 18.000 postponed diagnosis and 30.000 new diagnosis «lost»

Onco-hematology: diagnosis, treatments, hospitalizations, surgeries: comparison january-october 2020 vs 2019



© IQVIA 2020. All rights reserved.

**ONCOLOGY** 

In order to monitor the impact of Covid it is foreseen a quarterly monitoring of real world data for 2021, integrated by a semestral survey and with further analysis and ad-hoc insights



15

≣IOV

€QVIA

#### Contacts

Isabella Cecchini Principal, PMR isabella.cecchini@iqvia.com +39 334 60 80 897

Elena De Santo Engagement Manager, Oncology elena.desanto@iqvia.com +39 348 881 9160 Francesca Rampi Principal, Real World Data francesca.rampi@iqvia.com +39 348 0029874

Marco Zamboni Sr Consultant, Real World Data <u>marco,zamboni@iqvia.com</u> +39 349 4030392

© 2021. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.